[Exelixis,Inc。] Exelixis,Inc。宣布发起XL114的第一阶段I阶段试验的剂量升级阶段,这是一种抑制卡11-BCL10-MALT1复合物的新型抗癌化合物,作为单一疗法in patients with non-Hodgkin’s lymphoma who have received prior standard therapies.
[BriaCell Therapeutics Corp.] BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced that the US FDA has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer.